QUOTED. 8 October 2019. Mary Anne Heino.
Diagnostic imaging agent company Lantheus Holdings will acquire Progenics Pharmaceuticals, the developer of radiotherapeutics and imaging agents to treat cancer, in an all-stock deal announced last week. See what Lantheus CEO Mary Anne Heino said about the deal here.
“The combination of Lantheus and Progenics has a clear and compelling rationale. This transaction leverages our core capabilities, including proven commercial and operational expertise while diversifying our revenue streams by broadening our presence in emerging uses of radioisotopes in precision diagnostics, as well as the exciting field of radiopharmaceuticals in oncology treatment.” – Mary Anne Heino, CEO, Lantheus Holdings Inc.
Click here for a free trial of Medtech Insight